A Study of ART4215 for the Treatment of Advanced or Metastatic Solid Tumors
Status:
Recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
This clinical trial is evaluating a drug called ART4215 in participants with advanced or
metastatic solid tumors. The main goals of this study are to:
- Find the recommended dose of ART4215 that can be given safely to participants alone and
in combination with talazoparib
- Learn more about the side effects of ART4215 alone and in combination with talazoparib
- Learn more about the effectiveness of ART4215 alone and in combination with talazoparib